Follow Us:

social twitter box white 32 social facebook box blue 32social linkedin box blue 32ISN Blog

Tuesday, 14 October 2014 14:56

Anticoagulation in Kidney Disease: Options and Considerations audioicon

Rate this item
(9 votes)

Additional Info

  • Language: English
  • Contains Audio: Yes
  • Content Type: Presentations
  • Source: Other sources
  • Year: 2014
  • Members Only: No
Read 1990 times Last modified on Friday, 17 October 2014 14:56

UKidney is a provider of educational tools for the study and practice of nephrology, hypertension management, and kidney transplantation. The site features essential educational contributions from major opinion leaders in nephrology.


Leave your comments

Post comment as a guest

Your comments are subject to administrator's moderation.
terms and condition.
  • Guest - Bennet

    Great overview.

    from Portland, OR, USA
  • Guest - Gerardo

    I was ISN member before, I want to remain part of ISN, like active member.
    what I need to do to make my payments and current status.

    from Mexico City, Federal District, Mexico
  • Guest - Sarah Aloudat

    Thanks for the great work. Tinzaparin is one LMWH that I had not have to use, but would strongly consider it.
    I wished if you have touched on VKA use in ESRD patients.

    from Ontario, Canada
  • Guest - gabriel mendez

    excelent review. very interesting

    from Maracaibo, Venezuela
  • Guest - Julia Schneider

    excellent literature review of use of low molecular weight heparin and unfractionated heparin. I am more aware now about the use of tinzaparin and I am looking forward to the results of TRIVET study. Enoxaprin is frequently used at our institution for ESRD patient population at reduced dosages, however, there is clearly not enough data on the regimen to be used in such patients. Risk of life threatening bleeading (intracranial bleeding) needs to be weighed against the risk of deadly PE's. These are very difficult decisions to make for both patients and clinicians.

    from Chicago, IL, USA
  • Guest - Pavlos Malindretos, MD, MSc, PhD

    Very nice lecture! There might be one more point you might wish to comment, and it really trouble us in every day practice regarding ESRD patients under dialysis. Increased risk of calciphylaxis due to VKA use. What alternatives do we have? for example when treating a patient under dialysis who also suffers from AF. Thanks again for the presentation!

    from Thessalia, Greece

Global Operations Center

Rue des Fabriques 1
1000 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact


Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact